查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1383628

Crispr 基因組治療市場 - 全球行業規模、佔有率、趨勢、機會和預測，2018-2028 年按疾病和治療類型、交付方法、最終用戶、標靶基因改造、地區、競爭預測和機會細分，2018-2028F

Crispr Genomic Cure Market-Global Industry Size, Share, Trends, Opportunity, & Forecast, 2018-2028 Segmented By Disease & Therapy Type, Delivery Method, End User, Targeted Genetic Modification, Region, Competition Forecast & Opportunities, 2018-2028F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球 Crispr 基因組治療市場價值為 18.9 億美元，預計到 2028 年，預測期內將出現令人印象深刻的成長，複合CAGR為29.21%。全球CRISPR 基因組治療市場是生物技術和醫療保健產業中快速發展的領域。 CRISPR（成簇規則間隔短回文重複序列）技術徹底改變了基因編輯，並為治療各種遺傳性疾病帶來了巨大希望。

主要市場促進因素

科技的快速進步

市場概況
預測期 2024-2028
2022 年市場規模 18.9億美元
2028 年市場規模 87.4億美元
2023-2028 年CAGR 29.21%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

CRISPR 技術的早期迭代在精度和潛在的脫靶效應方面存在局限性。然而，不懈的研究努力已經在這些領域取得了顯著的進展。先進的 CRISPR 系統和增強的遞送方法最大限度地減少了脫靶效應，使基因編輯更安全、更可預測。這種準確性的提高增強了人們對 CRISPR 治療潛力的信心，並吸引了更多的投資。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細目
  • 管道細分（按狀態）
  • 按研究應用分類的管道細分
  • 按地區分類的管道明細
  • 臨床試驗熱圖

第 6 章：全球 Crispr 基因組治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、傳染病、神經系統疾病、心血管疾病、血液疾病、代謝疾病等）
    • 依治療類型（基因編輯、基因治療、細胞治療、免疫治療）
    • 依遞送方式（體內、離體）
    • 按最終用戶（醫院和診所、研究所、生物技術和製藥公司）
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖
    • 依疾病類型
    • 按治療類型
    • 按交貨方式
    • 按最終用戶
    • 透過標靶基因改造
    • 按地區

第 7 章：北美 Crispr 基因組治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、傳染病、神經系統疾病、心血管疾病、血液疾病、代謝疾病等）
    • 依治療類型（基因編輯、基因治療、細胞治療、免疫治療）
    • 依遞送方式（體內、離體）
    • 按最終用戶（醫院和診所、研究所、生物技術和製藥公司）
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章：歐洲 Crispr 基因組治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、傳染病、神經系統疾病、心血管疾病、血液疾病、代謝疾病等）
    • 依治療類型（基因編輯、基因治療、細胞治療、免疫治療）
    • 依遞送方式（體內、離體）
    • 按最終用戶（醫院和診所、研究所、生物技術和製藥公司）
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙

第 9 章：亞太地區 Crispr 基因組治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、傳染病、神經系統疾病、心血管疾病、血液疾病、代謝疾病等）
    • 依治療類型（基因編輯、基因治療、細胞治療、免疫治療）
    • 依遞送方式（體內、離體）
    • 按最終用戶（醫院和診所、研究所、生物技術和製藥公司）
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國

第 10 章：南美洲 Crispr 基因組治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、傳染病、神經系統疾病、心血管疾病、血液疾病、代謝疾病等）
    • 依治療類型（基因編輯、基因治療、細胞治療、免疫治療）
    • 依遞送方式（體內、離體）
    • 按最終用戶（醫院和診所、研究所、生物技術和製藥公司）
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲 Crispr 基因組治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依疾病類型（遺傳性疾病、癌症、傳染病、神經系統疾病、心血管疾病、血液疾病、代謝疾病等）
    • 依治療類型（基因編輯、基因治療、細胞治療、免疫治療）
    • 依遞送方式（體內、離體）
    • 按最終用戶（醫院和診所、研究所、生物技術和製藥公司）
    • 透過標靶基因修飾（單基因修飾、多基因修飾、全基因組修飾）
    • 按國家/地區
  • MEA：國家分析
    • 南非 Crispr 基因組治療
    • 沙烏地阿拉伯 Crispr 基因組治愈
    • 阿拉伯聯合大公國 Crispr 基因組治愈
    • 科威特 Crispr 基因組治療

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Merck KGaA
    • Takara Bio Inc
    • Lonza Group AG
    • Horizon Discovery Group Ltd
    • Genscript Biotech Corp
    • Synthego Corp
    • Precision BioSciences Inc
    • Mammoth Biosciences Inc
    • Thermo Fisher Scientific Inc
    • Intellia Therapeutics Inc

第 16 章：策略建議

第 17 章：關於我們與免責聲明

簡介目錄
Product Code: 17664

Global Crispr Genomic Cure Market has valued at USD 1.89 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 29.21% through 2028. The global CRISPR genomic cure market is a rapidly evolving sector within the biotechnology and healthcare industries. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized gene editing and holds immense promise for treating various genetic and hereditary diseases.

Key Market Drivers

Rapid Technological Advancements

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.89 Billion
Market Size 2028USD 8.74 Billion
CAGR 2023-202829.21%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Early iterations of CRISPR technology had limitations in terms of precision and the potential for off-target effects. However, relentless research efforts have led to significant improvements in these areas. Advanced CRISPR systems and enhanced delivery methods have minimized off-target effects, making gene editing safer and more predictable. This improved accuracy has boosted confidence in CRISPR's therapeutic potential and attracted increased investment.

Scientists continue to develop novel CRISPR tools and techniques that expand the capabilities of gene editing. Innovations like CRISPR-Cas9 variants and base editing systems allow for more precise modifications of genetic material. These tools open up new possibilities for treating diseases that were once considered untreatable, thereby expanding the market's horizons.

Automation and high-throughput screening methods have accelerated the drug discovery process in the pharmaceutical industry. CRISPR technology has benefited immensely from these advancements, enabling researchers to test thousands of genetic combinations rapidly. This increased efficiency is particularly valuable in identifying potential drug targets and therapeutic approaches, expediting the development of CRISPR-based therapies.

As CRISPR technology has matured, the costs associated with genome editing have decreased. This cost reduction has made CRISPR more accessible to a broader range of researchers and organizations, fostering a competitive market landscape. Lower costs also mean that more research projects can be initiated, leading to a higher likelihood of groundbreaking discoveries.

Efficient delivery of CRISPR components into target cells is crucial for successful genome editing. Advances in delivery systems, such as viral vectors and nanoparticles, have significantly improved the efficiency and safety of CRISPR-based therapies. These advancements have been pivotal in translating laboratory successes into clinical applications.

Technological advancements have enabled multiplex editing, allowing scientists to modify multiple genes simultaneously. This capability has profound implications for the treatment of complex genetic diseases and the development of combination therapies. It also enhances the efficiency of genetic engineering for applications in agriculture and biotechnology.

CRISPR technology is not limited to healthcare; it has found applications in agriculture, biotechnology, and environmental conservation. Rapid advancements in these areas have expanded the market's scope, creating diverse revenue streams and business opportunities.

Expanding Applications

Beyond its initial focus on genetic diseases, CRISPR technology is now being investigated for a wide array of therapeutic applications. Researchers are exploring its potential in treating various types of cancer, neurodegenerative disorders, infectious diseases, and even cardiovascular conditions. This expansion of therapeutic opportunities has amplified the market's potential for growth as it reaches a more extensive patient base.

One of the most promising applications of CRISPR technology lies in the field of cancer immunotherapy. CRISPR is being employed to engineer immune cells, such as T-cells, to target and destroy cancer cells more effectively. This innovative approach has the potential to revolutionize cancer treatment and has attracted significant investment and research.

CRISPR offers new hope to individuals with rare and ultra-rare genetic diseases that have long lacked effective treatments. By precisely editing the genetic mutations responsible for these conditions, CRISPR-based therapies hold the potential to provide life-changing solutions for patients who previously had none.

Expanding beyond human healthcare, CRISPR is making waves in agriculture. It enables the development of crops with improved traits, such as disease resistance, increased yield, and enhanced nutritional content. As the world grapples with food security challenges and environmental concerns, CRISPR's role in agriculture is set to grow, bolstering the market.

CRISPR can be used to combat infectious diseases by engineering organisms to resist pathogens. This could be particularly relevant in addressing emerging infectious diseases and antibiotic resistance. CRISPR-based interventions for infectious disease prevention could become essential tools in public health.

Gene therapy, a promising avenue for treating genetic disorders, has experienced significant advancements due to CRISPR. By refining the delivery and precision of gene-editing tools, CRISPR has accelerated the development of gene therapies, expanding their application to a broader range of diseases.

Investment and Funding

Investment and funding provide the lifeblood for research and development (R&D) efforts in the CRISPR genomic cure market. These financial resources enable scientists and researchers to pursue groundbreaking studies, conduct clinical trials, and explore new therapeutic avenues. With ample funding, R&D initiatives can progress swiftly, accelerating the development of CRISPR-based treatments.

Investment is crucial for the growth of startups and biotech companies specializing in CRISPR technology. Many of these firms are at the forefront of innovation, actively engaged in translating laboratory discoveries into viable therapies. Substantial funding not only sustains these companies but also attracts top talent and fosters an environment conducive to innovation.

Conducting clinical trials is an essential step in bringing CRISPR-based therapies to market. These trials require substantial financial backing for patient recruitment, data analysis, and regulatory compliance. Investment and funding facilitate the progress of these trials, potentially expediting the timeline to market approval.

Investment often comes in the form of partnerships between biotech startups and established pharmaceutical companies. These collaborations leverage the strengths of both entities, combining innovative research with the resources and infrastructure needed for large-scale clinical trials and commercialization. Such partnerships can significantly boost the growth of the CRISPR market.

Investment enables the development of cutting-edge CRISPR tools and technologies. Innovations like improved CRISPR-Cas systems, delivery methods, and automation are critical for enhancing the efficiency, precision, and safety of gene editing. These technological advancements are instrumental in broadening CRISPR's applications and increasing its market potential.

Global Collaboration

Global collaboration breaks down geographical barriers, enabling researchers from diverse backgrounds and regions to share knowledge and insights. This cross-pollination of ideas and expertise fuels innovation by bringing together a wide range of perspectives and approaches to solving complex scientific challenges.

Collaborative efforts often involve the pooling of resources and funding. Institutions and organizations from different parts of the world can jointly invest in ambitious CRISPR research projects and clinical trials. This collective financial support allows for larger-scale studies and faster progression of therapies to market.

Large-scale clinical trials, essential for validating the safety and efficacy of CRISPR-based therapies, often require extensive resources and patient populations. Global collaborations enable the recruitment of diverse patient cohorts across multiple countries, expediting the clinical trial process and bringing therapies to patients sooner.

Collaboration among regulatory agencies across borders is critical for establishing consistent and globally accepted guidelines for CRISPR-based therapies. Harmonized regulations reduce bureaucratic hurdles and create a more predictable pathway for market approval, facilitating the growth of the CRISPR genomic cure market.

Global collaborations provide access to diverse patient data sets and genetic information from different populations. This diversity is vital for developing CRISPR therapies that are effective for a wide range of patients and genetic backgrounds, ensuring the market's inclusivity.

Collaboration extends beyond research and development. It also includes knowledge transfer and capacity building. Institutions in emerging economies can benefit from partnerships with more established research centers, gaining access to expertise and technology that accelerates their contributions to the CRISPR market.

Key Market Challenges

Ethical and Regulatory Hurdles

Perhaps one of the most significant challenges is the ethical and regulatory landscape surrounding CRISPR technology. The ethical debate over gene editing in humans, particularly germline editing, remains a contentious issue. Regulatory agencies worldwide are grappling with the need to strike a balance between fostering innovation and ensuring safety and ethical considerations.

Off-Target Effects and Precision

Achieving precise gene editing without causing unintended off-target effects remains a technical challenge. Ensuring the accuracy of CRISPR-Cas systems is essential to prevent unintended genetic alterations and potential long-term consequences for patients.

Long-Term Safety Concerns

The long-term safety of CRISPR-based therapies is a topic of ongoing research and concern. As these therapies progress through clinical trials, monitoring patients for potential side effects and unforeseen consequences is crucial to building confidence in the technology's safety and efficacy.

Key Market Trends

Therapeutic Expansion Beyond Genetic Disorders

One of the most significant trends is the expansion of CRISPR-based therapies beyond the realm of genetic disorders. While genetic diseases remain a crucial focus, researchers are increasingly exploring the use of CRISPR for treating complex diseases like cancer, neurodegenerative disorders, and infectious diseases. The versatility of CRISPR technology allows for targeted interventions in a wide range of conditions.

Multiplex Editing and Combination Therapies

Multiplex gene editing, the simultaneous modification of multiple genes, is becoming increasingly feasible with CRISPR technology. This trend opens the door to combination therapies, where multiple gene targets are addressed to treat complex diseases. This approach is especially relevant in cancer treatment, where a combination of edits may be required for optimal outcomes.

Enhanced Delivery Methods

Effective and safe delivery of CRISPR components to target cells is a key challenge. Upcoming trends in the development of novel delivery methods, such as nanoparticles and viral vectors, will improve the efficiency and precision of gene editing. This will broaden the applicability of CRISPR therapies and make them more accessible.

Segmental Insights

Disease Type Insights

Based on the category of Disease Type, Genetic disorders are poised to dominate the global CRISPR genomic cure market in 2022 due to several compelling factors. Firstly, the prevalence of genetic disorders worldwide is alarmingly high, affecting millions of individuals and their families. This widespread demand for effective treatments has spurred intense research and development efforts within the biotechnology and pharmaceutical industries, with CRISPR-based therapies emerging as a promising solution. Additionally, the versatility and precision of CRISPR technology make it a frontrunner in the race to address genetic disorders, allowing for targeted modifications and corrections of faulty genes. Furthermore, the growing awareness of CRISPR's potential to revolutionize healthcare, coupled with advancements in regulatory frameworks, investment influx, and international collaborations, is creating a conducive environment for the expansion of the CRISPR genomic cure market. As the understanding of genetics deepens and CRISPR-based therapies continue to prove their efficacy, the dominance of genetic disorder treatments in this market is not only foreseeable but also a significant driver of innovation and growth in the life sciences sector.

End User Insights

Hospitals and clinics are poised to dominate the global CRISPR genomic cure market in 2022 for several compelling reasons. Firstly, these healthcare institutions serve as the primary points of contact for patients seeking medical interventions, making them the ideal distribution channels for CRISPR-based therapies. As the awareness and adoption of CRISPR technology increases among medical professionals, hospitals and clinics become natural hubs for the administration of these cutting-edge treatments. Moreover, the regulatory environment is gradually adapting to accommodate genomic therapies, further facilitating their integration into traditional healthcare settings. Hospitals and clinics also have the infrastructure and expertise to conduct clinical trials and research studies, which are essential for refining and expanding the applications of CRISPR in healthcare. This combination of patient access, medical expertise, and research capabilities positions hospitals and clinics as central players in the global CRISPR genomic cure market, ensuring widespread accessibility and advancing the frontier of precision medicine.

Regional Insights

North America is poised to dominate the global CRISPR genomic cure market in 2022 for several compelling reasons. Firstly, the region boasts a robust ecosystem of biotechnology and pharmaceutical companies, many of which are pioneers in CRISPR technology research and development. These companies have access to substantial resources, attracting top talent and fostering innovation in the field. Additionally, North America benefits from a well-established regulatory framework that, while stringent, provides a clear path for the approval and commercialization of CRISPR-based therapies, ensuring their rapid adoption. Furthermore, the region's strong emphasis on healthcare infrastructure, research institutions, and academic collaborations enhances the development and application of CRISPR technology. Lastly, a large patient population and high healthcare expenditure levels in North America create a significant market demand for innovative treatments, making it an attractive destination for CRISPR genomic cures. Collectively, these factors position North America at the forefront of the global CRISPR genomic cure market, driving innovation, accessibility, and market leadership in this transformative field of medicine.

Key Market Players

Merck KGaA

Takara Bio Inc

Lonza Group AG

Horizon Discovery Group Ltd

Genscript Biotech Corp

Synthego Corp

Precision BioSciences Inc

Mammoth Biosciences Inc

Thermo Fisher Scientific Inc

Intellia Therapeutics Inc

Report Scope:

In this report, the Global Crispr Genomic Cure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crispr Genomic Cure Market, By Disease Type:

  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disorders
  • Blood Disorders
  • Metabolic Disorders
  • Others

Crispr Genomic Cure Market, By Therapy Type:

  • Gene Editing
  • Gene Therapy
  • Cell Therapy
  • Immunotherapy

Crispr Genomic Cure Market, By Delivery Method:

  • In vivo
  • Ex vivo

Crispr Genomic Cure Market, By End User:

  • Hospitals & Clinics
  • Research Institutes
  • Biotechnology & Pharmaceutical Companies

Crispr Genomic Cure Market, By Targeted Genetic Modification:

  • Single Gene Modification
  • Multiple Gene Modification
  • Genome-wide Modification

Crispr Genomic Cure Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Crispr Genomic Cure Market.

Available Customizations:

  • Global Crispr Genomic Cure market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Crispr Genomic Cure Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 6.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 6.2.3. By Delivery Method (In vivo, Ex vivo)
    • 6.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 6.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 6.2.6. By Region
    • 6.2.7. By Company (2022)
  • 6.3. Product Market Map
    • 6.3.1. By Disease Type
    • 6.3.2. By Therapy Type
    • 6.3.3. By Delivery Method
    • 6.3.4. By End User
    • 6.3.5. By Targeted Genetic Modification
    • 6.3.6. By Region

7. North America Crispr Genomic Cure Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 7.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 7.2.3. By Delivery Method (In vivo, Ex vivo)
    • 7.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 7.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Crispr Genomic Cure Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy Type
        • 7.3.1.2.3. By Delivery Method
        • 7.3.1.2.4. By End User
        • 7.3.1.2.5. By Targeted Genetic Modification
    • 7.3.2. Canada Crispr Genomic Cure Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy Type
        • 7.3.2.2.3. By Delivery Method
        • 7.3.2.2.4. By End User
        • 7.3.2.2.5. By Targeted Genetic Modification
    • 7.3.3. Mexico Crispr Genomic Cure Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy Type
        • 7.3.3.2.3. By Delivery Method
        • 7.3.3.2.4. By End User
        • 7.3.3.2.5. By Targeted Genetic Modification

8. Europe Crispr Genomic Cure Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 8.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 8.2.3. By Delivery Method (In vivo, Ex vivo)
    • 8.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 8.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Crispr Genomic Cure Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy Type
        • 8.3.1.2.3. By Delivery Method
        • 8.3.1.2.4. By End User
        • 8.3.1.2.5. By Targeted Genetic Modification
    • 8.3.2. United Kingdom Crispr Genomic Cure Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy Type
        • 8.3.2.2.3. By Delivery Method
        • 8.3.2.2.4. By End User
        • 8.3.2.2.5. By Targeted Genetic Modification
    • 8.3.3. France Crispr Genomic Cure Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy Type
        • 8.3.3.2.3. By Delivery Method
        • 8.3.3.2.4. By End User
        • 8.3.3.2.5. By Targeted Genetic Modification
    • 8.3.4. Italy Crispr Genomic Cure Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy Type
        • 8.3.4.2.3. By Delivery Method
        • 8.3.4.2.4. By End User
        • 8.3.4.2.5. By Targeted Genetic Modification
    • 8.3.5. Spain Crispr Genomic Cure Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy Type
        • 8.3.5.2.3. By Delivery Method
        • 8.3.5.2.4. By End User
        • 8.3.5.2.5. By Targeted Genetic Modification

9. Asia-Pacific Crispr Genomic Cure Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 9.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 9.2.3. By Delivery Method (In vivo, Ex vivo)
    • 9.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 9.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Crispr Genomic Cure Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy Type
        • 9.3.1.2.3. By Delivery Method
        • 9.3.1.2.4. By End User
        • 9.3.1.2.5. By Targeted Genetic Modification
    • 9.3.2. Japan Crispr Genomic Cure Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy Type
        • 9.3.2.2.3. By Delivery Method
        • 9.3.2.2.4. By End User
        • 9.3.2.2.5. By Targeted Genetic Modification
    • 9.3.3. India Crispr Genomic Cure Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy Type
        • 9.3.3.2.3. By Delivery Method
        • 9.3.3.2.4. By End User
        • 9.3.3.2.5. By Targeted Genetic Modification
    • 9.3.4. Australia Crispr Genomic Cure Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Disease Type
        • 9.3.4.2.2. By Therapy Type
        • 9.3.4.2.3. By Delivery Method
        • 9.3.4.2.4. By End User
        • 9.3.4.2.5. By Targeted Genetic Modification
    • 9.3.5. South Korea Crispr Genomic Cure Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Disease Type
        • 9.3.5.2.2. By Therapy Type
        • 9.3.5.2.3. By Delivery Method
        • 9.3.5.2.4. By End User
        • 9.3.5.2.5. By Targeted Genetic Modification

10. South America Crispr Genomic Cure Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 10.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 10.2.3. By Delivery Method (In vivo, Ex vivo)
    • 10.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 10.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Crispr Genomic Cure Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy Type
        • 10.3.1.2.3. By Delivery Method
        • 10.3.1.2.4. By End User
        • 10.3.1.2.5. By Targeted Genetic Modification
    • 10.3.2. Argentina Crispr Genomic Cure Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy Type
        • 10.3.2.2.3. By Delivery Method
        • 10.3.2.2.4. By End User
        • 10.3.2.2.5. By Targeted Genetic Modification
    • 10.3.3. Colombia Crispr Genomic Cure Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy Type
        • 10.3.3.2.3. By Delivery Method
        • 10.3.3.2.4. By End User
        • 10.3.3.2.5. By Targeted Genetic Modification

11. Middle East and Africa Crispr Genomic Cure Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 11.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 11.2.3. By Delivery Method (In vivo, Ex vivo)
    • 11.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 11.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Crispr Genomic Cure Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Disease Type
        • 11.3.1.2.2. By Therapy Type
        • 11.3.1.2.3. By Delivery Method
        • 11.3.1.2.4. By End User
        • 11.3.1.2.5. By Targeted Genetic Modification
    • 11.3.2. Saudi Arabia Crispr Genomic Cure Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Disease Type
        • 11.3.2.2.2. By Therapy Type
        • 11.3.2.2.3. By Delivery Method
        • 11.3.2.2.4. By End User
        • 11.3.2.2.5. By Targeted Genetic Modification
    • 11.3.3. UAE Crispr Genomic Cure Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Disease Type
        • 11.3.3.2.2. By Therapy Type
        • 11.3.3.2.3. By Delivery Method
        • 11.3.3.2.4. By End User
        • 11.3.3.2.5. By Targeted Genetic Modification
    • 11.3.4. Kuwait Crispr Genomic Cure Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Disease Type
        • 11.3.4.2.2. By Therapy Type
        • 11.3.4.2.3. By Delivery Method
        • 11.3.4.2.4. By End User
        • 11.3.4.2.5. By Targeted Genetic Modification

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Merck KGaA
    • 15.6.2. Takara Bio Inc
    • 15.6.3. Lonza Group AG
    • 15.6.4. Horizon Discovery Group Ltd
    • 15.6.5. Genscript Biotech Corp
    • 15.6.6. Synthego Corp
    • 15.6.7. Precision BioSciences Inc
    • 15.6.8. Mammoth Biosciences Inc
    • 15.6.9. Thermo Fisher Scientific Inc
    • 15.6.10. Intellia Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer